Schizophrenia.com

CVN058 shows promise in Phase Ib schizophrenia cognition study

8 Likes

Very early phases but I like that it’s biomarker based. And tested on actual people with schizophrenia, not healthy volunteers.

According to the company, the small-molecule type 3 serotonin receptor antagonist was able to normalise mismatch negativity (MMN) brainwaves, which act as a biomarker of cortical dysfunction.

2 Likes

Nice post 151515.

2 Likes

As we say,in the case,if you do not put in your account the existence of the psychotic factor and its effect on the self-thoughts pathways ,the treatment becomes an experimental therapeutics ,that does not target the actual casual agents who is responsible to induces all symptoms